Division of Population Health Sciences and Education, St George's University of London, Tooting, London SW17 0RE, UK.
Br J Clin Pharmacol. 2011 Jul;72(1):157-61. doi: 10.1111/j.1365-2125.2011.03980.x.
To examine the effect of β-adrenoceptor blocker treatment on cancer survival.
In a UK primary care database, we compared patients with a new cancer diagnosis receiving β-adrenoceptor blockers regularly (n= 1406) with patients receiving other antihypertensive medication (n= 2056).
Compared with cancer patients receiving other antihypertensive medication, patients receiving β-adrenoceptor blocker therapy experienced slightly poorer survival (HR = 1.18, 95% CI 1.04, 1.33 for all β-adrenoceptor blockers; HR = 1.21, 95% CI 0.94, 1.55 for non-selective β-adrenoceptor blockers). This poorer overall survival was explained by patients with pancreatic and prostate cancer with no evidence of an effect on survival for patients with lung, breast or colorectal cancer. Analysis in a cancer-free matched parallel cohort did not suggest selection bias masked a beneficial effect.
Our study does not support the hypothesis that β-adrenoceptor blockers improve survival for common cancers.
研究β受体阻滞剂治疗对癌症患者生存的影响。
在英国初级保健数据库中，我们比较了新诊断患有癌症且经常接受β受体阻滞剂治疗的患者（n=1406）与接受其他降压药物治疗的患者（n=2056）。
与接受其他降压药物治疗的癌症患者相比，接受β受体阻滞剂治疗的患者生存状况略差（所有β受体阻滞剂的 HR=1.18，95%CI1.04，1.33；非选择性β受体阻滞剂的 HR=1.21，95%CI0.94，1.55）。这种总体生存率较差的情况可以解释为患有胰腺癌和前列腺癌的患者，而对于患有肺癌、乳腺癌或结直肠癌的患者，其生存没有证据表明存在影响。在无癌症的匹配平行队列中进行的分析并未表明选择偏差掩盖了有益的效果。
我们的研究不支持β受体阻滞剂可改善常见癌症患者生存的假设。
